Reply to the Letter by Deleu: Rivastigmine in the Treatment of Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1421-9913|46|2|111-111

ISSN： 0014-3022

Source： European Neurology, Vol.46, Iss.2, 2001-08, pp. : 111-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Rivastigmine in the Treatment of Alzheimer’s Disease

By  

European Neurology, Vol. 46, Iss. 2, 2001-08 ,pp. : 110-110

Karger

Access to resources Recommend Favorite

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 150-162

Karger

Access to resources Recommend Favorite

Does Rivastigmine Improve Cognitive Functions or Disability in Patients with Alzheimer’s Disease?

By  

Neuroepidemiology, Vol. 23, Iss. 4, 2004-07 ,pp. : 209-210

Karger

Access to resources Recommend Favorite

Treatment of Alzheimer’s Disease with Clioquinol

By  

Dementia and Geriatric Cognitive Disorders, Vol. 12, Iss. 6, 2001-10 ,pp. : 408-414

Karger

Access to resources Recommend Favorite

Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer’s Disease Patients

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 2-3, 2005-02 ,pp. : 126-133

Karger

Access to resources Recommend Favorite